Kala Bio (KALA) Gross Margin (2019 - 2022)

Kala Bio (KALA) posted Gross Margin of 97.38% for Q3 2022, up 527.3% sequentially from 15.52% in Q2 2022, and up 2699.0% YoY from 3.48% in Q3 2021.

Kala Bio (KALA) Gross Margin (2019 - 2022) Analysis & Trends

Kala Bio has reported Gross Margin for 4 years, with the latest figure at 97.38% in Q3 2022.

Quarterly Gross Margin rose 2699.0% year-over-year to 97.38% in Q3 2022, while the trailing twelve-month figure through Dec 2022 was 34.22% (down 2933.0% YoY) and the FY2022 annual result came in at 34.22%, down 2933.0% from the prior year.
Gross Margin grew to 97.38% in Q3 2022 per KALA's latest filing, from 15.52% in the prior quarter.
Over five years, Gross Margin peaked at 97.38% in Q3 2022 and troughed at 8.88% in Q2 2020.
A 4-year average of 55.58% and a median of 66.7% in 2021 frame the typical range for Gross Margin.
The sharpest annual moves came in 2020 and 2021: Gross Margin sank 7400 bps in 2020, then surged 5782 bps in 2021.
Over 4 years, Gross Margin stood at 36.69% in 2019, then gained by 7 bps to 39.28% in 2020, then slumped by 40 bps to 23.6% in 2021, then soared by 313 bps to 97.38% in 2022.
According to Business Quant data, Gross Margin over the past three periods registered 97.38%, 15.52%, and 43.51% for Q3 2022, Q2 2022, and Q1 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.90 Bn	132.05 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	91.59%
3	Argenx Se	65.73 Bn	60.55 Bn	1.37 Bn	90.43%
4	Moderna	58.33 Bn	53.19 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.72 Bn	28.42 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.27 Bn	9.88 Bn	668.28 Mn	63.27%
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.25 Bn	26.41 Bn	-	-
10	Kala Bio	10.06 Mn	10.06 Mn	-	-

Download Data